Market Place
Sourcing Support
Addex Provisional 2024 Q3 Results Showed Loss Compared to Q2 2024
11 Nov 2024 //
GLOBENEWSWIRE
Addex Reports 2024 Half Year Financial Results & Update
30 Sep 2024 //
GLOBENEWSWIRE
Addex Reports Net Profit For 2024 Half-Year Results
19 Sep 2024 //
GLOBENEWSWIRE
Addex To Participate In H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Addex and Indivior Select Clinical Candidates from GABAB Modulator Collaboration
27 Aug 2024 //
GLOBENEWSWIRE
Addex And Indivior Select Clinical Candidates From GABAB Modulator Research
27 Aug 2024 //
GLOBENEWSWIRE
Indivior Picks Up Addex`s Addiction Asset After Epilepsy Drug Flop
27 Aug 2024 //
FIERCE BIOTECH
CIRM Funds CAR-T NXC-201 US AL Amyloidosis Trial
24 Jul 2024 //
GLOBENEWSWIRE
Addex’s Partner Discontinues ADX71149 development in Epilepsy
22 Jul 2024 //
GLOBENEWSWIRE
Addex Presents Positive Results From GABAB PAM Cough Program At 13th LICS
15 Jul 2024 //
GLOBENEWSWIRE
Addex To Present At 13th London International Cough Symposium
12 Jul 2024 //
GLOBENEWSWIRE
Addex Shareholders Approve All Resolutions at Annual General Meeting
01 Jul 2024 //
GLOBENEWSWIRE
Addex Reports Q1 2024 Financials, Provides Corporate Update
06 Jun 2024 //
GLOBENEWSWIRE
Addex Convenes Annual General Meeting 2024
05 Jun 2024 //
GLOBENEWSWIRE
Addex To Report Q1 2024 Results And Host Call On June 6
30 May 2024 //
GLOBENEWSWIRE
Addex`s Janssen-partnered epilepsy drug fails phase 2 trial
29 Apr 2024 //
FIERCE BIOTECH
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
29 Apr 2024 //
GLOBENEWSWIRE
Addex to Present at the Swiss Biotech Day 2024
19 Apr 2024 //
GLOBENEWSWIRE
Addex Reports 2023 Financials, Corporate Update
18 Apr 2024 //
GLOBENEWSWIRE
Addex Therapeutics to Release Full-Year 2023 Financial Results
11 Apr 2024 //
GLOBENEWSWIRE
Addex to Present at the Bio-Europe Spring 2024 Conference
14 Mar 2024 //
GLOBENEWSWIRE
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright
31 Jan 2024 //
GLOBENEWSWIRE
Addex to Present at the Swiss Equities Baader Conference
09 Jan 2024 //
GLOBENEWSWIRE
Addex to Present at Biotech Showcase„¢ 2024
05 Jan 2024 //
GLOBENEWSWIRE
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
19 Dec 2023 //
GLOBENEWSWIRE
Addex Creates Treasury Shares
14 Dec 2023 //
GLOBENEWSWIRE
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
29 Nov 2023 //
GLOBENEWSWIRE
Addex Convenes Extraordinary General Meeting
28 Nov 2023 //
GLOBENEWSWIRE
Addex Therapeutics to Release Third Quarter 2023 Financial Results
23 Nov 2023 //
GLOBENEWSWIRE
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
14 Nov 2023 //
GLOBENEWSWIRE
Addex Regains Nasdaq Listing Compliance
08 Nov 2023 //
GLOBENEWSWIRE
Addex Announces Participation in the Bio-Europe 2023 Conference
02 Nov 2023 //
GLOBENEWSWIRE
Addex Completes ADS Ratio Change
19 Oct 2023 //
GLOBENEWSWIRE
Addex Announces Plan to Implement ADS Ratio Change
06 Oct 2023 //
GLOBENEWSWIRE
Addex mGlu2 NAM Cognition Program Receives ‚¬4 Million Grant
20 Sep 2023 //
GLOBENEWSWIRE
Addex Announces Participation in the H.C. Wainwright 25th Annual Conference
06 Sep 2023 //
GLOBENEWSWIRE
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
05 Sep 2023 //
GLOBENEWSWIRE
Addexs Dipraglurant Development in Post-Stroke Recovery Supported by Data
04 Sep 2023 //
GLOBENEWSWIRE
Addex Reports 2023 Half Year and Second Quarter Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Addex Therapeutics to Release Half-Year 2023 Financial Results
04 Aug 2023 //
GLOBENEWSWIRE
Addex Modulator Program to Receive Additional CHF2.7 Million from Indivior
03 Aug 2023 //
GLOBENEWSWIRE
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
24 Jul 2023 //
GLOBENEWSWIRE
Addex Increases Issued Share Capital to Create Treasury Shares
15 Jun 2023 //
GLOBENEWSWIRE
Addex Shareholders Approve All Resolutions at Annual General Meeting
01 Jun 2023 //
GLOBENEWSWIRE
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
18 May 2023 //
GLOBENEWSWIRE
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study™s
10 May 2023 //
GLOBENEWSWIRE
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
10 May 2023 //
GLOBENEWSWIRE
Addex Convenes Annual General Meeting 2023
04 May 2023 //
GLOBENEWSWIRE
Addex Therapeutics to Release Q1 2023FYR and Host Conference Call on May 11,2023
03 May 2023 //
GLOBENEWSWIRE
Addex Completes $5.0 Million Equity Financing
05 Apr 2023 //
GLOBENEWSWIRE
Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor
04 Apr 2023 //
GLOBENEWSWIRE
Addex Raises $5.0 Million in Equity Financing
03 Apr 2023 //
GLOBENEWSWIRE
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
30 Mar 2023 //
GLOBENEWSWIRE
Addex to Release Full-Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Addex Announces Upcoming Conferences it will participate for H1 2023
16 Mar 2023 //
GLOBENEWSWIRE
Addex Regains Nasdaq Listing Compliance
09 Feb 2023 //
GLOBENEWSWIRE
Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Part 1
06 Feb 2023 //
GLOBENEWSWIRE
Addex Provides Corporate Update and Financial Guidance
19 Jan 2023 //
GLOBENEWSWIRE
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB
08 Dec 2022 //
GLOBENEWSWIRE
Addex Therapeutics to Report Third Quarter 2022 Financial Results
02 Nov 2022 //
GLOBENEWSWIRE
